Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new case report reveals that systemic mastocytosis (SM) can hide behind acute myeloid leukemia (AML), only becoming visible after induction therapy reduces the leukemic burden. The overlap condition — SM-AML — is rare but carries a grim prognosis, with median survival as low as 5.4 months in KIT-mutated cases. Clinicians are urged to consider SM evaluation in all KIT-positive AML patients.
A case report published in Cureus highlights a diagnostic blind spot in hematologic malignancies: systemic mastocytosis (SM) can be completely obscured by concurrent acute myeloid leukemia (AML), only emerging after induction chemotherapy clears enough of the leukemic burden to reveal underlying mast cell proliferation.
In the reported case, a 48-year-old man was diagnosed with AML after presenting with leukocytosis, anemia, and thrombocytopenia — with no classic signs of mast cell disease. It wasn't until a day-14 bone marrow biopsy post-induction that clusters of mast cells became apparent, confirming SM-AML. Molecular testing identified a KIT exon 17 mutation, supporting a shared clonal origin between the mast cell and leukemic components. The case raises a broader concern: SM may be significantly underrecognized in KIT-positive AML, with some studies finding SM criteria met in up to 44% of KIT-positive AML patients.
By the Numbers:
Why it matters: SM-AML is a rare but deadly overlap that demands a dual treatment strategy — intensive AML therapy plus consideration of KIT inhibitors (avapritinib, midostaurin, or dasatinib) and allogeneic stem cell transplantation. Earlier recognition could open the door to more targeted, life-extending interventions.
